Open AccessMonitoring of Separate Pathogenetically Significant Biochemical Markers in Lacrimal Fluid, Ophthalmological Parameters with Combined Pathology of Diabetic Retinopathy and Age-Related Macular Degeneration on the Background Angioprotective and Antioxidant Therapy
Author(s) -
И. В. Воробьева
Publication year - 2018
Publication title -
oftalʹmologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 5
eISSN - 2500-0845
pISSN - 1816-5095
DOI - 10.18008/1816-5095-2018-2-189-199
Subject(s) - medicine , macular degeneration , ophthalmology , diabetic retinopathy , fundus (uterus) , capsule , retinopathy , visual acuity , ranibizumab , diabetes mellitus , surgery , endocrinology , bevacizumab , chemotherapy , botany , biology
Object : Optimization of treatment in early stages of combined fundus pathology diabetic retinopathy (DR without DME) and dry type of age-related macular degeneration (AMD AREDS I, II, III). Patients and methods: 120 people (150 eyes). Study group 1 (SG1) — control 60 people. (60 eyes); study group 2 (SG2) — 30 people. (30 eyes) — DRI without DME and AMD AREDS I, II, III) treatment: 1 year with angioprotective calcium dobezilate (Doxi- Hem®) dose of 500 mg 3 after 6 months, 500 mg once a day for 6 months and at the same time 1 year antioxidant agent (Retinorm) 1 capsule 3 times a day; study group 3 group (SG3) 30 people. (30 eyes) — with DRO and dry type of AMD (AREDS I, II, III) 1 year Retinorm 1 capsule 3 times a day; study group 4 (SG4) with DRI without DME — 30 people. (30 eyes) 1 year Doxi-Hem®. Monitoring: monthly standard ophthalmologic examination, control of diabetes mellitus (HbA1C) compensation, VEGF-A vascular endothelial growth factor in tear. Results. Visual acuity increased on the background of treatment in all three groups (IG2,3,4): in SG2 from 0.72 ± 0.02 to 0.87 ± 0.02, p 0.05. In IG4 visual acuity increased from 0.70 ± 0.02 to 0.78 ± 0.02, p 0.05. Conclusion . Combined therapy of angioprotective (Doxi-Hem®) and antioxidant therapy (Retinorm) with timely appointment at early dry stages of combined pathology (DR and AMD) will allow to stabilize, delay the development of severe forms of the disease.